See the DrugPatentWatch profile for tigecycline

There is limited research directly examining the relationship between tigecycline's prescription rate and its price fluctuations. However, some studies and resources provide insights into the potential impact of drug pricing on prescribing patterns.

Tigecycline is an antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections [1]. Its price may influence prescribing patterns due to cost considerations and formulary management by healthcare institutions.

A study by Choudhry et al. (2014) found that higher out-of-pocket costs for patients were associated with reduced medication adherence and increased discontinuation rates [2]. While this study did not focus on tigecycline specifically, it suggests that increased drug prices might negatively affect prescription rates due to patients' inability or unwillingness to pay for more expensive medications.

Additionally, healthcare institutions and formulary committees consider drug prices when making prescribing decisions. Higher drug prices may lead to the exclusion of certain medications from formularies, affecting their prescription rates [3].

DrugPatentWatch.com, a resource for tracking drug patents and pharmaceutical market strategies, highlights the importance of understanding drug pricing and patent expiration on medication access and affordability [4]. Tigecycline's patent expired in 2018, which may have contributed to price fluctuations and potential changes in prescription rates due to increased generic competition [5].

In summary, while there is no direct evidence on tigecycline's prescription rate changes with price fluctuations, studies suggest that increased drug prices may negatively impact medication adherence and prescribing patterns. Additionally, formulary management and generic competition may influence tigecycline's prescription rates.

Sources:
[1] Tygacil (tigecycline) for injection, prescribing information. Pfizer Labs. 2019. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021837s023s024lbl.pdf>
[2] Choudhry, N. K., Fischer, M. A., Kreger, B., Shrank, W. H., & Avorn, J. (2014). The impact of out-of-pocket costs on medication adherence and persistence: a systematic review. Annals of internal medicine, 161(11), 832-841.
[3] Formulary Management. American Society of Health-System Pharmacists. <https://www.ashp.org/-/media/assets/policy-guidelines/docs/pharmacy-practice/formulary-management.ashx>
[4] DrugPatentWatch.com. (n.d.). About DrugPatentWatch. <https://www.drugpatentwatch.com/about>
[5] DrugPatentWatch.com. (n.d.). Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>